Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
Founders Respond to Participant Needs to Drive Trial Retention
BERWYN, PA., Nov. 14, 2022 – Mural Health Technologies, Inc., a new global provider of clinical trials technology, today announced the launch of its new technology platform, Mural Link, which has been built to make it easy to be a participant in global clinical research studies. Among other planned participant-facing feature sets, Mural Link is excited to launch the industry’s next-generation participant payment technology, designed by Sam Whitaker, the inventor of the industry’s first participant payment technology product, the ClinCard. Mural Link’s payments technology is complimented by three other initial features sets, namely transportation, two-way messaging and participant feedback, which will help participants overcome existing barriers to enrolling in and remaining in clinical trials.
In 2008, Sam Whitaker founded Greenphire and invented the first participant payment technology, the ClinCard. Over the last 15 years, technologies have evolved and the world has changed how it operates. Since the ClinCard’s launch, there has been an undeniable shift to the digitization of all aspects of day-to-day life, including personal financial management, transportation, and communication. Individuals have also become increasingly empowered in their relationships with the parts of the healthcare ecosystem that they interact with in their daily lives. Unfortunately, although not surprising, clinical trial technology has not adapted to meet the needs of an evolving world and modern-day clinical research participants.
To address the existing disparity, Sam and the Mural Health team have built a platform that focuses all of its effort on improving the patient experience and assisting participant populations that struggle to engage with and remain in studies. Mural Link’s next-generation participant payment technology is strategically leveraged by the platform in order to introduce and deliver other features that benefit of both patients and their caregivers. All of the features of the Mural Link platform are designed to improve site level operations and deliver greater strategic value to sponsors beyond those offered by point-solutions delivering payments via prepaid debit card. Mural Health’s platform will also offer unique structures to benefit other eClinical technologies and CROs.
“This time, I am not thinking of the payment technology as the end-goal but rather as a strategic first step that will help Mural Health accomplish a much larger product vision and, consequently, have a more profound impact on the global patient population.” said Sam. “We want to improve participants’ experience in trials. We want to make it easy to be a part of a trial, so more diverse populations can enroll in and stay engaged after randomization. We have a big vision and our entire team is passionate about the journey that lies ahead.”
“Payments are important, but Mural Link is built to do much more than just deliver payment to participants. The platform also helps participants get to their appointment (transportation) without incurring expense, helps participants communicate with site personnel (secure two-way in-app communications), and empowers the participant by giving them a voice, to provide feedback, which quantifies satisfaction across the participant’s trial journey. Mural Link is the first product that will give the sponsor satisfaction and retention data in real time across all the sites in a study. The platform will empower the study to identify at-risk participants in order to proactively remediate issues and retain individuals who would otherwise drop out.”
Mural Health will be debuting its platform at the CNS Summit in Boca Raton, FL on November 17-20, 2022.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/d6d18ff8-39d3-4047-b805-cff46eed1dc6.png?optimizer=image&width=360&aspect_ratio=3:4)
bit.bio chooses Automata for automating an aspect of its production of iPSC derived human cells
26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC (induced pluripotent stem cell)-derived human cell products.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/2a446651-4aa1-454e-8fe7-b0f1714fecd5.png?optimizer=image&width=360&aspect_ratio=3:4)
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/57d78f63-2598-4a6f-ae73-80d29698546c.png?optimizer=image&width=360&aspect_ratio=3:4)
Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium
SOMERSET, N.J. – January 26, 2023 – Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the opening of a new commercial-scale plasmid DNA (pDNA) manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/7ce8f780-11bc-451e-b11e-aa0b6d632178.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher and AstraZeneca partner to Develop Solid Tissue, Blood-Based Companion Diagnostic Test
24 January -- CARLSBAD, Calif.--(BUSINESS WIRE)-- As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/1b83c600-5a94-4609-a117-c3cc2e65f43d.png?optimizer=image&width=360&aspect_ratio=3:4)
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
